Alteration of androgen receptor cofactor in prostate cancer
Shiota, M.; Yokomizo, A.; Naito, S.; Fujimoto, N.
Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 5): 108-111
2011
ISSN/ISBN: 0047-1852 PMID: 22207952 Document Number: 651819
Document emailed within 1 workday
Related Documents
Jarrard, D.F.; Kinoshita, H.; Shi, Y.; Sandefur, C.; Hoff, D.; Meisner, L.F.; Chang, C.; Herman, J.G.; Isaacs, W.B.; Nassif, N. 1998: Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells Cancer Research 58(23): 5310-5314Pettaway, C.A. 1999: Racial differences in the androgen/androgen receptor pathway in prostate cancer Journal of the National Medical Association 91(12): 653-660
Bastos, D.A.; Dzik, C.; Rathkopf, D.; Scher, H.I. 2014: Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer Oncology 28(8): 693-699
Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319
Gao, J.; Isaacs, J.T. 1998: Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells Cancer Research 58(15): 3299-3306
Vis, A.é N.; van Moorselaar, R.J.A. 2019: Androgen receptor inhibitors in prostate cancer: new drugs, but for which patient? Nederlands Tijdschrift Voor Geneeskunde 163
Huang, S-Pin.; Chou, Y-Her.; Chang, W-Shaing.Wayne.; Wu, M-Tsang.; Yu, C-Cheng.; Wu, T.; Lee, Y-Huei.; Huang, J-Khing.; Wu, W-Jeng.; Huang, C-Hsiung. 2003: Androgen receptor gene polymorphism and prostate cancer in Taiwan Journal of the Formosan Medical Association 102(10): 680-686
Jenster, G. 1999: The role of the androgen receptor in the development and progression of prostate cancer Seminars in Oncology 26(4): 407-421
Magi-Galluzzi, C.; Xu, X.; Hlatky, L.; Hahnfeldt, P.; Kaplan, I.; Hsiao, P.; Chang, C.; Loda, M. 1997: Heterogeneity of androgen receptor content in advanced prostate cancer Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 10(8): 839-845
Nguyen, M.M.; Wang, Z. 2008: Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer Minerva Urologica e Nefrologica 60(1): 15-29
Narita, D.; Raica, M.; Suciu, C.; Cîmpean, A.; Anghel, A. 2006: Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer Folia Histochemica et Cytobiologica 44(3): 165-172
Jackson, K.M.; Frazier, M.C.; Harris, W.B. 2007: Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer Anticancer Research 27(3b): 1483-1488
Chen, W.; Yan, C.; Pu, J.; Hou, J.; Wen, D.; Guo, Z. 2004: Regulation of EGF-receptor expression by TGFalpha in human prostate androgen-unresponsive cancer cells Zhonghua Nan Ke Xue 10(8): 595-597
Gu, Y.; Kim, K-Hong.; Ko, D.; Srivastava, S.; Moul, J.W.; McLeod, D.G.; Rhim, J.S. 2005: Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line Anticancer Research 25(1a): 1-8
Pan, T.-F.; Liang, C.-Z.; Chen, X.-G.; Fan, S. 2013: Mammalian target of rapamycin regulates androgen receptor and Akt phosphorylation in prostate cancer 22RV1 cells Zhonghua Nan Ke Xue 19(12): 1068-1071
Olapade-Olaopa, E.O.; Moscatello, D.K.; MacKay, E.H.; Sandhu, D.P.S.; Terry, T.R.; Wong, A.J.; Habib, F.K. 2004: Alterations in the expression of androgen receptor, wild type-epidermal growth factor receptor and a mutant epidermal growth factor receptor in human prostate cancer African Journal of Medicine and Medical Sciences 33(3): 245-253
Izbicka, E.; MacDonald, J.R.; Davidson, K.; Lawrence, R.A.; Gomez, L.; Von Hoff, D.D. 1999: 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells Anticancer Research 19(2a): 1285-1291
Amler, L.C.; Agus, D.B.; LeDuc, C.; Sapinoso, M.L.; Fox, W.D.; Kern, S.; Lee, D.; Wang, V.; Leysens, M.; Higgins, B.; Martin, J.; Gerald, W.; Dracopoli, N.; Cordon-Cardo, C.; Scher, H.I.; Hampton, G.M. 2000: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1 Cancer Research 60(21): 6134-6141
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Xia, S.; Wang, Y.; Tang, X. 2001: Androgen receptor isoforms expression and its novel cDNA cloning in human prostate Zhonghua Yi Xue Za Zhi 81(24): 1500-1503